SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115: 163442.
  • 2
    Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 170911.
  • 3
    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, for The VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 15208.
  • 4
    Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092102.
  • 5
    Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA. Cardiovascular risks of nonsteroidal anti-inflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009; 2: 15563.
  • 6
    Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Br Med J 2006; 332: 13028.
  • 7
    McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 163344.
  • 8
    Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006; 99: 13240.
  • 9
    García Rodríguez LA, Patrignani P. The ever growing story of cyclo-oxygenase inhibition. Lancet 2006; 368: 17457.
  • 10
    Funk CD, Fitzgerald GA. Cox-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007; 50: 4709.
  • 11
    Grosser T, Fries S, Fitzgerald GA. Biological basis for the cardiovascular consequences of Cox 2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 415.
  • 12
    Bolli R, Shinmura K, Tang XL, Yiru G, Buddhadeb D. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 2002; 55: 50619.
  • 13
    Andersohn F, Suissa S, Garbe E. Cyclooxygenase inhibitors and cardiovascular risk. JAMA 2007; 297: 5867.
  • 14
    Henry DA, McGettigan P. Cyclooxygenase inhibitors and cardiovascular risk – reply. JAMA 2007; 297: 5878.
  • 15
    Rodrigues DA. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos 2005; 33: 156775.
  • 16
    Martinez C, Blanco G, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, Diaz-Rubio M, Agúndez JA. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol 2004; 141: 2058.
  • 17
    Ulrich CM, Whitton J, Yu J-H, Sibert J, Sparks R, Potter JD, Bigler J. PTGS2 (COX-2) −765G >C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidem Biomar 2005; 14: 6169.
  • 18
    Cippollone F, Toniato E, Martinotti S, Fazia M Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, Mezzetti A. Identification of new elements of plaque stability (INES) study group. A polymorphism in the cyclooxygenase-2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004; 291: 22218.
  • 19
    Colaizzo D, Fofi L, Tiscia G, Guglielmi R, Cocomazzi N, Massimiliano P, Maurizio M, Danilo T. The COX-2 G/C -765 polymorphism may modulate the occurrence of cerebrovascular ischemia. Blood Coagul Fibrin 2006; 17: 936.
  • 20
    Morgan TM, Krumholz HM, Lifton RP, Spertus JA. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 2007; 297: 155161.
  • 21
    Hegener HH, Diehl KA, Kurth T, Gaziano JM, Ridker PM, Zee YL. Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case–control approach. J Thromb Haemost 2006; 4: 171822.
  • 22
    Rudock ME, Liu Y, Ziegler JT, Allen SG, Lehtinen AB, Freedman BI, Carr JJ, Langefeld CD, Bowden DW. Association of polymorphisms in cyclooxygenase (COX) -2 with coronary and carotid calcium in the diabetes heart study. Atherosclerosis 2009; 203: 45965.
  • 23
    Lee Y-S, Kim H, Wu T-X, Wang X-M, Dionne RA. Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin Pharmacol Ther 2006; 79: 40718.
  • 24
    Orbe J, Beloqui O, Rodriguez JA, Belzunce MS, Roncal C, Páramo JA. Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clin Chim Acta 2006; 368: 13843.
  • 25
    PRISM Study Group: The platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators. Inhibition of the Platelet Glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non–Q-wave myocardial infarction. N Engl J Med 1998; 338: 148897.
  • 26
    McEvoy M, Smith W, D'Este C, Duke J, Peel R, Schofield P, Scott R, Byles J, Henry D, Ewald B, Hancock S, Smith D, Attia J. Cohort profile: the Hunter Community Study. Int J Epidemiol 2010; 39: 145263.
  • 27
    Page J, Henry D. Consumption of NSAIDs and the development of heart failure in elderly subjects. Arch Intern Med 2000; 160: 77784.
  • 28
    McGettigan P, Han P, Jones L, Whitaker D, Henry D. Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. Br J Clin Pharmacol 2008; 65: 92734.
  • 29
    Attia J, Thakkinstian A, Wang Y, Lisa Lincz L, Parsons M, Sturm J, McGettigan P, Scott R, Meldrum C, Levi C. The PAI-1 4G/5G gene polymorphism and ischemic stroke: an association study and meta-analysis. J Stroke Cerebrovasc Dis 2007; 16: 1739.
  • 30
    Carter KW, McCaskie PA, Palmer LJ, SimHap GUI. An intuitive graphical user interface for genetic association analysis. BMC Bioinformatics 2008; 9: 55762.
  • 31
    Botto LD, Khoury MJ. Facing the challenge of gene-environment interaction: the two-by-four table and beyond. Am J Epidemiol 2001; 153: 101620.
  • 32
    Maguire J, Thakkinstian A, Attia J, Bisset L, Sturm J, Scott R, Levi C. Impact of COX-2 rs5275, rs20417 and GPIIIa rs5918 polymorphisms on 90 day ischaemic stroke functional outcome: a novel association. J Stroke Cerebrovasc Dis 2010; 20: 13444.
  • 33
    Khan F, Howe L, Falcone D. Extracellular matrix-induced cyclooxygenase-2 regulates macrophage proteinase expression. J Biol Chem 2004; 279: 2203946.
  • 34
    Pavlovic S, Du B, Sakamoto K Khan KMF, Natarajan C, Breyer RM, Dannenberg AJ, Falcone DJ. Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. J Biol Chem 2006; 281: 332128.
  • 35
    Dixon D, Tolley N, Bemis-Standoli K Martinez ML, Weyrich AS, Morrow JD, Prescott SM, Zimmerman GA. Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signalling. J Clin Invest 2006; 116: 272738.
  • 36
    Rocca B, Secchiero P, Ciabattoni G Ranelletti FO, Catani L, Guidotti L, Melloni E, Maggiano N, Zauli G, Patrono C. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002; 99: 76349.
  • 37
    Yellon D, Downey J. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003; 83: 111351.
  • 38
    Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004; 109: 146871.
  • 39
    Kuehl GE, Lampe JW, Potter JD, Bigler J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 2005; 33: 102735.
  • 40
    Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, Miners JO. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000; 10: 67985.
  • 41
    Vogel U, Segel S, Dethlefsen C, Tjønneland A, Saber AT, Wallin H, Jensen MK, Schmid EB, Andersen PS, Overvad K. Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome. Atherosclerosis 2010; 209: 15562.
  • 42
    St. Germaine CG, Bogaty P, Boyer L, Hanley J, Engert JC, Brophy JM. Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs. Am J Cardiol 2010; 105: 17405.